Skip to main content
Premium Trial:

Request an Annual Quote

Caliper, Ambion to Co-Develop Microfluidics-Based RNA-Amplification Tool

NEW YORK, Oct. 28 - Caliper Technologies, Ambion, and an unnamed third party will use a $1.6 million NIH grant to develop an automated microfluidics-based RNA-amplification technology, the firms said today.


According to the companies, the proposed system will include a Caliper microfluidic LabChip product and a reagent kit made by Ambion to amplify reactions on the LabChip.


Caliper scientists will develop the chip while Ambion will develop the assay and tweak reagents. It was not immediately clear how long the R&D will take. Both companies together with the third party will pitch in to build the instrument.


The companies said they hope the new technology will increase throughput, decrease sample requirements, and boost consistency associated with RNA amplification.


The firms will use a $1.6 SBIR grant awarded to privately held Ambion by the NIH's National Institute of General Medical Sciences.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.